Cell: Isolated strong SARS-CoV-2 neutralizing antibodies from patients with new coronary pneumonia.

July 12, 2020 /PRNewswire/ -- --- An important line of defense against the new coronavirus SARS-CoV-2 is neutralizing the formation of antibodiesthese antibodies can eliminate intruders and have great potential to prevent and treat SARS-CoV-2 infectionnow, in a new study, researchers from the University of Cologne, the German Infection Research Center, the University of Marburg, the University of Wuerzburg, the University of Tubingen, the University of Frankfurt, the University of Munich and the Weizmann Institute of Science in Israel further illustrate how these antibodies form and isolate the powerful SARS-CoV-2 neutralizing antibodiesthey are currently working with Bollinger Ingham for further identification and development of these antibodiesexpect sit into clinical development later this yearrelated findings were published online July 7, 2020 in the journal Cell, with the title "Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing anti-with-the-covid-19 patients"picture from NIAID-RML"Our goal is to better understand the immune response to SARS-CoV-2 and to identify highly potent antibodies that can be used to prevent and treat COVID-19," explained Professor Florian Klein,'s communications author and director of the Institute of Virology at the University hospital in Cologne and lead researcher at the German Infection Research Center"We think these antibodies work in a few weeks and may prevent COVID-19 during this time," added DrChristoph Kreer, co-author of the" paper" co-author of the paper is DrMatthias Zehner of the University Hospital of Colognethe researchers studied the SARS-CoV-2 antibody response sons of 12 people recovering from COVID-19they detected more than 4,000 SARS-CoV-2-specific B cells at a single cell level and were able to partially decode the body fluid immune response to SARS-CoV-2they reconstructed 255 antibodies in the lab and tested their ability to neutralise the new coronavirus SARS-CoV-2 by Stephan Becker's lab at Philip University in Marlboroughthey found a total of 28 neutral antibodies"Interestingly, many antibodies have only a small number of mutations, " said DrZehnermeans that only minor changes are required to effectively identify and neutralise the virus" In fact, in blood samples collected before the COVID-19 pandemic, the researchers found that B cells carried antibody characteristics similar to those found in SARS-CoV-2 and antibodiesthis may indicate that SARS-CoV-2 antibodies are easy to form and that the active vaccine may provide rapid protectionthese neutralizing antibodies have been developed for the prevention and treatment of COVID-19In addition, these antibodies can also be used for "post-exposure prevention"For now, these antibodies will be used after contact with an infected person"This form of intervention could be particularly relevant to prevent localoutbreak outbreaks and prevent disease progression in high-risk populations," said ProfessorKlein" the researchers expect the first clinical trials to take place by the end of 2020(bioon.com) References: 1Christoph Kreer et alLongitudinal of the opto-germline SARS-CoV-2-neutralizing anti from bodies COVID-19 patientsCell, 2020, doi: 10.1016/j.cell.2020.06.044.2.Neutraling antibodies in the battle against COVID-19.